703 related articles for article (PubMed ID: 30871514)
1. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
[TBL] [Abstract][Full Text] [Related]
2. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
3. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
[TBL] [Abstract][Full Text] [Related]
4. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Nutr Metab (Lond); 2018; 15():63. PubMed ID: 30263038
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial.
Aghasi M; Koohdani F; Qorbani M; Nasli-Esfahani E; Ghazi-Zahedi S; Khoshamal H; Keshavarz A; Sotoudeh G
J Sci Food Agric; 2019 Jun; 99(8):3933-3940. PubMed ID: 30701554
[TBL] [Abstract][Full Text] [Related]
6. The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial.
Aghasi M; Ghazi-Zahedi S; Koohdani F; Siassi F; Nasli-Esfahani E; Keshavarz A; Qorbani M; Khoshamal H; Salari-Moghaddam A; Sotoudeh G
BMC Complement Altern Med; 2018 Jan; 18(1):18. PubMed ID: 29343256
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial.
Safarpour P; Daneshi-Maskooni M; Vafa M; Nourbakhsh M; Janani L; Maddah M; Amiri FS; Mohammadi F; Sadeghi H
BMC Fam Pract; 2020 Feb; 21(1):26. PubMed ID: 32033527
[TBL] [Abstract][Full Text] [Related]
9. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Moradi F; Kooshki F; Nokhostin F; Khoshbaten M; Bazyar H; Pourghassem Gargari B
J Trace Elem Med Biol; 2021 Jan; 63():126659. PubMed ID: 33045675
[TBL] [Abstract][Full Text] [Related]
11. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
12. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
[TBL] [Abstract][Full Text] [Related]
13. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
J Trace Elem Med Biol; 2020 Dec; 62():126635. PubMed ID: 32932174
[TBL] [Abstract][Full Text] [Related]
14. The effect of cardamom supplementation on serum lipids, glycemic indices and blood pressure in overweight and obese pre-diabetic women: a randomized controlled trial.
Fatemeh Y; Siassi F; Rahimi A; Koohdani F; Doostan F; Qorbani M; Sotoudeh G
J Diabetes Metab Disord; 2017; 16():40. PubMed ID: 29026804
[TBL] [Abstract][Full Text] [Related]
15. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial.
Jafari-Maskouni S; Shahraki M; Daneshi-Maskooni M; Dashipour A; Shamsi-Goushki A; Mortazavi Z
Nutr Metab (Lond); 2020; 17():74. PubMed ID: 32863846
[TBL] [Abstract][Full Text] [Related]
17. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of Chaihu Shugan San () on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance.
Jiang WN; Li D; Jiang T; Guo J; Chen YF; Wang J; Zhou Y; Yang CY; Tang CP
Chin J Integr Med; 2018 Feb; 24(2):125-132. PubMed ID: 27164963
[TBL] [Abstract][Full Text] [Related]
19. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
[TBL] [Abstract][Full Text] [Related]
20. The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Ghanbari P; Raiesi D; Alboebadi R; Zarejavid A; Dianati M; Razmi H; Bazyar H
BMC Complement Med Ther; 2024 May; 24(1):192. PubMed ID: 38755622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
